Argos HIV Immunotherapy Offers Potential Reprieve From Antiretrovirals
This article was originally published in The Pink Sheet Daily
Executive Summary
Through automation and economies of scale, Argos believes its personalized HIV immunotherapy can be "cost competitive with current therapies" with a dosing scheme that offers freedom from ART regimens.
You may also be interested in...
Hepatitis C Opportunities Light Up Infectious Disease Partnering Landscape
"Without question, hepatitis C is the number one exciting area in infectious diseases," insists Paul Zhang, a principal in the health care advisory group Easton Associates, LLC.
Hepatitis C Opportunities Light Up Infectious Disease Partnering Landscape
"Without question, hepatitis C is the number one exciting area in infectious diseases," insists Paul Zhang, a principal in the health care advisory group Easton Associates, LLC.
It's A Start: Experimental HIV Vaccine Regimen Cuts Disease Risk By A Third In Thai Volunteers
Six-year U.S. Army/NIH-sponsored study conducted in 16,000-plus Thai adults shows 31.2% decreased risk of infection, but better efficacy is needed.